文献速递其他结缔组织病

阿巴西普治疗原发性干燥综合征可减弱滤泡辅助性T细胞依赖的B细胞过度活化

Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome.
PubMed 文献 · Arthritis Rheumatol · 2017-08-13

结果显示阿巴西普选择性减少循环Tfh细胞和Treg细胞,降低ICOS表达及IL-21、CXCL13、抗SSA/SSB水平,浆母细胞减少,且循环Tfh细胞ICOS表达降低与ESSDAI评分下降显著相关。

要点

  • 阿巴西普选择性减少循环Tfh细胞和Treg细胞,其他CD4+效应T细胞亚群不受影响。
  • 循环Tfh细胞ICOS表达降低与治疗期间ESSDAI评分下降显著相关。
  • 停药后所有参数逐渐恢复至基线水平。

核心结论

  • 阿巴西普治疗原发性干燥综合征可减少循环Tfh细胞数量及T细胞活化标志物ICOS表达,减弱Tfh细胞依赖的B细胞过度活化,可能解释其疗效。

研究设计与样本

  • 检测血清抗SSA/抗SSB及T细胞相关细胞因子水平,并在基线和治疗后检查腮腺组织中ICOS和IL-21蛋白表达。
  • 采用广义估计方程分析实验室参数变化与ESSDAI系统疾病活动度的关联。

主要发现

  • 阿巴西普选择性降低循环Tfh细胞和Treg细胞的百分比和数量,其他CD4+效应T细胞亚群未受影响。
  • 循环CD4+ T细胞活化标志物ICOS表达及腮腺组织ICOS蛋白表达下降。
  • 循环Tfh细胞ICOS表达降低与治疗期间较低ESSDAI评分显著相关。
  • 血清IL-21、CXCL13、抗SSA和抗SSB水平下降,循环浆母细胞减少。
  • 治疗停止后所有参数逐渐恢复至基线水平。

关键数值与推荐

  • 循环Tfh细胞ICOS表达降低与ESSDAI评分下降显著相关(原文未报告具体相关系数或P值)。
  • 血清IL-21、CXCL13、抗SSA和抗SSB水平下降(原文未报告具体数值)。
  • 循环浆母细胞减少(原文未报告具体数值)。

临床怎么用

  • 阿巴西普可能通过减少循环Tfh细胞数量和ICOS表达来减弱B细胞过度活化,可用于理解其在原发性干燥综合征中的潜在作用机制。
  • 治疗期间循环Tfh细胞ICOS表达降低与ESSDAI评分改善相关,但需进一步研究验证其作为疗效标志物的价值。

局限性

  • 停药后参数恢复基线,长期疗效及机制未涉及。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the effect of abatacept (CTLA-4Ig), which limits T cell activation, on homeostasis of CD4+ T cell subsets and T cell-dependent B cell hyperactivity in patients with primary Sjögren's syndrome (SS). METHODS: Fifteen patients with primary SS treated with abatacept were included. Circulating CD4+ T cell and B cell subsets were analyzed by flow cytometry at baseline, during the treatment course, and after treatment was completed. CD4+ effector T cell subsets and Treg cells were identified based on expression of CD45RA, CXCR3, CCR6, CCR4, CXCR5, programmed death 1, inducible costimulator (ICOS), and FoxP3. Serum levels of anti-SSA/anti-SSB and several T cell-related cytokines were measured. Expression of ICOS and interleukin-21 (IL-21) protein was examined in parotid gland tissue at baseline and after treatment. Changes in laboratory parameters and associations with systemic disease activity (EULAR Sjögren's Syndrome Disease Activity Index [ESSDAI]) over time were analyzed using generalized estimating equations. RESULTS: Abatacept selectively reduced percentages and numbers of circulating follicular helper T (Tfh) cells and Treg cells. Other CD4+ effector T cell subsets were unaffected. Furthermore, expression of the activation marker ICOS by circulating CD4+ T cells and expression of ICOS protein in parotid gland tissue declined. Reduced ICOS expression on circulating Tfh cells correlated significantly with lower ESSDAI scores during treatment. Serum levels of IL-21, CXCL13, anti-SSA, and anti-SSB decreased. Among circulating B cells, plasmablasts were decreased by treatment. After cessation of treatment, all parameters gradually returned to baseline. CONCLUSION: Abatacept treatment in patients with primary SS reduces circulating Tfh cell numbers and expression of the activation marker ICOS on T cells. Lower numbers of activated circulating Tfh cells contribute to attenuated Tfh cell-dependent B cell hyperactivity and may underlie the efficacy of abatacept.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Verstappen GM, Meiners PM, Corneth OBJ, et al. Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome. Arthritis Rheumatol. 2017. PMID: 28564491. doi:10.1002/art.40165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。